Abcellera Biologics is trading 5.6% down at $6.10 today, consolidating recent gains amid broader volatility in growth and healthcare names.
- The stock's recent performance includes an 8.61% drop on July 16, which was largely attributed to profit-taking near 52-week highs and a rotation within the biotech sector.
- There is no fresh company-specific news or catalysts today; the market is currently looking ahead to the company's Q2 earnings release scheduled for August 5, 2026.